Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 525

Sort by

Sort Order Select

Journal Articles

Stage IIb High Risk Hodgkin Lymphoma Treated in the H10 and AHL2011 Trials: Similar Efficacy of Both Strategies and Prognostic Impact of Baseline Tmtv and PET2 Response

Cédric Rossi, MD PhD, Marc André, Clémentine Joubert, PhD, Catherine Fortpied, Pauline Brice, Bénédicte Deau-Fisher, MD, Herve Ghesquieres, MD PhD, Luc Mathieu Fornecker, MD PhD, Anne-Claire Gac, MD, Julien Lazarovici, Aspasia Stamatoullas, MD, John Raemakers, Massimo Federico, MD, Marie Maerevoet, MD, Sarah Bailly, MD, Salim Kanoun, MD, Michel Meignan, Anne Ségolène Cottereau, Rene-Olivier Casasnovas, MD

Blood (2019) 134 (Supplement_1): 128.

https://doi.org/10.1182/blood-2019-125976

Published: 2019

Journal Articles

Long-Term Follow-up of a PET-Guided Approach to Treatment of Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) in British Columbia (BC)

Laurie H Sehn, MD, David W. Scott, MBChB, PhD, Diego Villa, MD FRCPC, Alina S Gerrie, MD MPH, Ciara L Freeman, MSc, MBBChir, Christina Aquino Parsons, MD, Tom Pickles, MD, Andrea Lo, MD, Pedro Farinha, MD PhD, Graham W Slack, MD PhD, Don Wilson, MD, R. Petter Tonseth, MD, Joseph M. Connors, MD, Kerry J Savage, BSc, MD MSc

Blood (2019) 134 (Supplement_1): 401.

https://doi.org/10.1182/blood-2019-128722

Published: 2019

Journal Articles

Clinical Characteristics and Outcome of Biphenotypic Acute Leukemia: 10 Cases Report and Literature Review

Jifeng Yu, MD, Yingmei Li, MD, Haizhou Xing, Hui Sun, Dingming Wan, MD, Yanfang Liu, Xinsheng Xie, MD, Chong Wang, Ling Sun, MD PhD, Kai Sun, MD, Zhongxing Jiang, MD PhD

Blood (2019) 134 (Supplement_1): 5207.

https://doi.org/10.1182/blood-2019-127580

Published: 2019

Journal Articles

Lymphoma Occurring during Pregnancy: Obstetric Outcome and Overall Survival in a Series of 19 Patients

Anna Vanazzi, MD, Fedro Peccatori, MD, Barbara Buonomo, MD, Di Loreto Eugenia, MD, Giovanna Scarfone, MD, Stefano A Pileri, Corrado Tarella, MD

Blood (2019) 134 (Supplement_1): 5289.

https://doi.org/10.1182/blood-2019-127391

Published: 2019

Journal Articles

Implementing a Specialist Integrated Haematological Malignancy Imaging Reporting Paradigm to Lymphoma Radiology Assessment Can Significantly Improve the Quality of Data for Patient Management and Clinical Research

Preethika Mahalingam, MBBS, BSc, Sunil Iyengar, MBBS, FRCPath, PhD, Dima El-Sharkawi, Bhupinder Sharma, MBBS, BSc(Hons) BM FRCR

Blood (2019) 134 (Supplement_1): 5835.

https://doi.org/10.1182/blood-2019-126155

Published: 2019

Journal Articles

CD20 Is an Unstable Target in Primary-Refractory High-Grade Lymphomas

Ryan N Rys, BSc, BA, Dominique Geoffrion, BSc, Christopher Rushton, BSc, Miguel Alcaide, PhD, Raoul Santiago, MDMSc, Koren Kathleen Mann, PhD, Svetlana Dmitrienko, MD PhD, Tina Petrogiannis-Haliotis, MD PhD, Sarit Assouline, MD, Ryan D. Morin, PhD, Nathalie Johnson, MD

Blood (2019) 134 (Supplement_1): 1608.

https://doi.org/10.1182/blood-2019-127129

Published: 2019

Journal Articles

The DLBCL90 Double-Hit Gene Expression Signature Is Not Associated with Inferior Survival in Young High-Risk Patients with Diffuse Large B-Cell Lymphoma Treated with Dose-Intensive Immunochemotherapy

Kathrine T. Isaksen, MD, Klaus Beiske, MD PhD, Erlend B. Smeland, MD PhD, Judit Jørgensen, MD PhD, Marianne Brodtkorb, MD PhD, June Helen Myklebust, PhD, Mats Jerkeman, MD Professor, Leo Meriranta, MD, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Sirpa Leppa, MD PhD, David W. Scott, MBChB, PhD, Harald Holte, MD PhD, Yngvild Nuvin Blaker, MD PhD

Blood (2019) 134 (Supplement_1): 1485.

https://doi.org/10.1182/blood-2019-121467

Published: 2019

Journal Articles

V2 Trial: A Phase I Study of Venetoclax Combined with CPX-351 for Children, Adolescents and Young Adults with Relapsed or Refractory Acute Leukemia

Laura Agresta, MD, Maureen M O'Brien, MD, Kana Mizuno, PhD, Robin Norris, MD MS, MPH, Erin H. Breese, MD PhD, Christine L Phillips, MD, Karen Burns, MD, Benjamin Mizukawa, Lynn Lee, MD, Adam Lane, PhD, Robert B. Lorsbach, MD PhD, Thomas D. Ryan, MD PhD, Pankaj B. Desai, PhD, Alexander A. Vinks, PharmD, PhD, H. Leighton Grimes, PhD, John P Perentesis, Michael J. Absalon, MD PhD

Blood (2019) 134 (Supplement_1): 3830.

https://doi.org/10.1182/blood-2019-121514

Published: 2019

Journal Articles

Polatuzumab Vedotin, an Antibody-Drug Conjugate Targeting CD79b, Is a Highly Active Agent Against Burkitt Lymphoma and Primary Mediastinal B-Cell Lymphoma

Anthony N. Audino, MD, Matthew J. Barth, MD, Aradhana Tiwari, PhD, Dina Edani, MS, Janet Ayello, MS, MT(ASCP), Lauren Harrison, RN, MSN, Erin Morris, RN, BSN, Jessica C. Hochberg, MD, Stanton Goldman, MD, Christian Klein, PhD, Mitchell S Cairo, MD

Blood (2019) 134 (Supplement_1): 3963.

https://doi.org/10.1182/blood-2019-128580

Published: 2019

Journal Articles

Should a Bulky Mediastinal Mass ≥7cm in the Longest Dimension be Considered an Adverse Prognostic Factor in Patients with Advanced Hodgkin Lymphoma and Negative Interim PET/CT?

Eldad J Dann, MD, Rebeca Lopez-Alonso, Shunan Qi, Tania Mashiach, Michal Weiler-Sagie, Joachim Yahalom, MD

Blood (2019) 134 (Supplement_1): 4051.

https://doi.org/10.1182/blood-2019-122824

Published: 2019

Journal Articles

Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

Beth A. Christian, MD, Ying Huang, MS, MA, Sabarish Ayyappan, MBBS, Robert A Baiocchi, MD PhD, Jonathan E Brammer, MD, Narendranath Epperla, MDMS, Samantha Jaglowski, MDMPH, Basem M. William, MRCP,MD, Farrukh T. Awan, MD, Kami J. Maddocks, MD, Kristie A. Blum, MD

Blood (2019) 134 (Supplement_1): 4082.

https://doi.org/10.1182/blood-2019-126242

Published: 2019

Journal Articles

ZUMA-11: A Phase 1/2 Multicenter Study of Axicabtagene Ciloleucel (Axi-Cel) + Utomilumab Patients with Refractory Large B Cell Lymphoma

Ran Reshef, MDMSc, David B. Miklos, MD PhD, John M. Timmerman, MD, Caron A. Jacobson, MD MMSc, Nabila N. Bennani, MD, John M. Rossi, MS, Marika Sherman, MS, Lianqing Zheng, PhD, Jennifer Sun, MS, Gabrielle Palluconi, BS, Jenny J. Kim, MD MS, Michael D. Jain, MD PhD

Blood (2019) 134 (Supplement_1): 4084.

https://doi.org/10.1182/blood-2019-123772

Published: 2019

Journal Articles

Phase 2 Study of Alemtuzumab Added to Dose-Adjusted EPOCH-R in Relapsed and Refractory Aggressive B-Cell Lymphomas

Sanjal Desai, MD, Christopher Melani, MD, Kieron Dunleavy, MD, Stefania Pittaluga, MD PhD, Mark A. Ahlman, MD, Andrea Nicole Lucas, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Mark Roschewski, MD, Wyndham Wilson, MD

Blood (2019) 134 (Supplement_1): 4102.

https://doi.org/10.1182/blood-2019-127481

Published: 2019

Journal Articles

Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase 2 Study

N. Nora Bennani, MD, Grzegorz Nowakowski, MD, Lisa M. Rimsza, MD, Alex A Adjei, MD PhD, Laurence Doyle, Stephen M Ansell, MD PhD

Blood (2019) 134 (Supplement_1): 4090.

https://doi.org/10.1182/blood-2019-129104

Published: 2019

Journal Articles

Efficacy and Safety of PD-1 Inhibitor Plus GVD Chemotherapy in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (rrPMLBCL)

Qian Mei, PhD, Wenying Zhang, MD, Yang Liu, MD, Qingming Yang, MD, John E.J. Rasko, MBBS, PhD, Weidong Han, PhD MD

Blood (2019) 134 (Supplement_1): 4072.

https://doi.org/10.1182/blood-2019-121768

Published: 2019

Journal Articles

Highly Favorable Outcomes with Salvage Radiation Therapy Followed By Autologous Transplant in Relapsed and Refractory DLBCL Patients with Minimal or No Response to Salvage Chemotherapy

Joanna C Yang, MD MPH, Karen Chau, BA, Michael Scordo, MD, Craig S. Sauter, MD, Joachim Yahalom, MD

Blood (2019) 134 (Supplement_1): 4137.

https://doi.org/10.1182/blood-2019-131664

Published: 2019

Journal Articles

Impact of Lisocabtagene Maraleucel (liso-cel) Treatment on Health-Related Quality of Life and Health Utility in Patients (pts) with Relapsed/Refractory (R/R) Aggressive B Cell Non-Hodgkin Lymphoma (NHL): Transcend NHL 001

Donald L. Patrick, Annette Powers, Monika Parisi, Yeonhee Kim, Jacob Garcia, MD, Christine Dehner, David G. Maloney, MD PhD

Blood (2019) 134 (Supplement_1): 66.

https://doi.org/10.1182/blood-2019-127145

Published: 2019

Journal Articles

Impact of Interim FDG-PET (iPET) in the Outcomes of Patients with Aggressive B-Cell Lymphomas Receiving DA-EPOCH-R

Vania Phuoc, MD, Leidy Isenalumhe, MD, Hayder Saeed, MD, Celeste Bello, MD, Bijal Shah, MD, Lubomir Sokol, MD PhD, Julio Chavez

Blood (2019) 134 (Supplement_1): 2898.

https://doi.org/10.1182/blood-2019-122393

Published: 2019

Journal Articles

Prognostic Value of Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured By 18F-FDG PET-CT in Patients with T-Cell Lymphoblastic Lymphoma

Xiaoyan Feng, Xin Wen, Ling Li, Xin Li, Sun Zhenchang, Lei Zhang, Lugui Qiu, MD PhD, Mingzhi Zhang, MD PhD

Blood (2019) 134 (Supplement_1): 2851.

https://doi.org/10.1182/blood-2019-130091

Published: 2019

Journal Articles

CD19 CAR T-Cell Therapy in Patients with Relapse/Refractory DLBCL: Retrospective Analysis of the Eligibility Criteria

Blood (2019) 134 (Supplement_1): 2887.

https://doi.org/10.1182/blood-2019-129532

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Stage IIb High Risk Hodgkin Lymphoma Treated in the H10 and AHL2011 Trials: Similar Efficacy of Both Strategies and Prognostic Impact of Baseline Tmtv and PET2 Response

Long-Term Follow-up of a PET-Guided Approach to Treatment of Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) in British Columbia (BC)

Clinical Characteristics and Outcome of Biphenotypic Acute Leukemia: 10 Cases Report and Literature Review

Lymphoma Occurring during Pregnancy: Obstetric Outcome and Overall Survival in a Series of 19 Patients

Implementing a Specialist Integrated Haematological Malignancy Imaging Reporting Paradigm to Lymphoma Radiology Assessment Can Significantly Improve the Quality of Data for Patient Management and Clinical Research

CD20 Is an Unstable Target in Primary-Refractory High-Grade Lymphomas

The DLBCL90 Double-Hit Gene Expression Signature Is Not Associated with Inferior Survival in Young High-Risk Patients with Diffuse Large B-Cell Lymphoma Treated with Dose-Intensive Immunochemotherapy

V2 Trial: A Phase I Study of Venetoclax Combined with CPX-351 for Children, Adolescents and Young Adults with Relapsed or Refractory Acute Leukemia

Polatuzumab Vedotin, an Antibody-Drug Conjugate Targeting CD79b, Is a Highly Active Agent Against Burkitt Lymphoma and Primary Mediastinal B-Cell Lymphoma

Should a Bulky Mediastinal Mass ≥7cm in the Longest Dimension be Considered an Adverse Prognostic Factor in Patients with Advanced Hodgkin Lymphoma and Negative Interim PET/CT?

Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

ZUMA-11: A Phase 1/2 Multicenter Study of Axicabtagene Ciloleucel (Axi-Cel) + Utomilumab Patients with Refractory Large B Cell Lymphoma

Phase 2 Study of Alemtuzumab Added to Dose-Adjusted EPOCH-R in Relapsed and Refractory Aggressive B-Cell Lymphomas

Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase 2 Study

Efficacy and Safety of PD-1 Inhibitor Plus GVD Chemotherapy in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (rrPMLBCL)

Highly Favorable Outcomes with Salvage Radiation Therapy Followed By Autologous Transplant in Relapsed and Refractory DLBCL Patients with Minimal or No Response to Salvage Chemotherapy

Impact of Lisocabtagene Maraleucel (liso-cel) Treatment on Health-Related Quality of Life and Health Utility in Patients (pts) with Relapsed/Refractory (R/R) Aggressive B Cell Non-Hodgkin Lymphoma (NHL): Transcend NHL 001

Impact of Interim FDG-PET (iPET) in the Outcomes of Patients with Aggressive B-Cell Lymphomas Receiving DA-EPOCH-R

Prognostic Value of Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured By 18F-FDG PET-CT in Patients with T-Cell Lymphoblastic Lymphoma

CD19 CAR T-Cell Therapy in Patients with Relapse/Refractory DLBCL: Retrospective Analysis of the Eligibility Criteria

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only